Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
925.23
+0.80 (+0.09%)
Streaming Delayed Price
Updated: 2:36 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,122,497
Open
931.79
Bid (Size)
925.23 (3)
Ask (Size)
925.78 (2)
Prev. Close
924.43
Today's Range
921.19 - 939.30
52wk Range
516.57 - 972.53
Shares Outstanding
N/A
Dividend Yield
0.49%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Today 13:30 EDT
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Today 9:16 EDT
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and...
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+56.24%
+56.24%
1 Month
-2.66%
-2.66%
3 Month
+2.28%
+2.28%
6 Month
+19.40%
+19.40%
1 Year
+67.53%
+67.53%
More News
Read More
Why This Stock Could Be the Nvidia of Healthcare
Today 7:30 EDT
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
September 24, 2024
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Via
MarketBeat
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
September 23, 2024
Via
Benzinga
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
September 20, 2024
Via
Benzinga
Looking Into Eli Lilly's Recent Short Interest
September 17, 2024
Via
Benzinga
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
September 24, 2024
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Unpacking the Latest Options Trading Trends in Eli Lilly
September 17, 2024
Via
Benzinga
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
September 22, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
September 21, 2024
Via
The Motley Fool
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
September 21, 2024
Via
Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
September 20, 2024
Via
The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
September 20, 2024
Via
Benzinga
Topics
Fraud
Exposures
Legal
Why Tandem Diabetes Care Stock Thrashed the Market Today
September 19, 2024
Via
The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
September 19, 2024
Via
The Motley Fool
Prediction: This Will be Eli Lilly's Next Big Move.
September 19, 2024
Via
The Motley Fool
Why ResMed Stock Tumbled by 5% Today
September 18, 2024
Via
The Motley Fool
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
September 18, 2024
Via
The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
September 18, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.